Bio-Path Holdings, Inc. announced that Dr. Ulrich W. Mueller has joined the Company as Chief Operating Officer. Dr. Mueller will be responsible for the Company's drug development, licensing and intellectual property activities, including managing the Company's clinical trials, pre-clinical and research and development efforts. Dr. Mueller, 47, was previously a Vice President at the Fred Hutchinson Center Research Center.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.91 USD | -5.91% | -4.50% | -79.37% |
May. 15 | Transcript : Bio-Path Holdings, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
Apr. 19 | Bio-Path Closes $1.2 Million Share Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.37% | 2.99M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.80% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- BPTH Stock
- News Bio-Path Holdings, Inc.
- Bio-Path Holdings, Inc. Appoints Ulrich W. Mueller as Chief Operating Officer